WO2009014524A3 - Thérapie photodynamique antimicrobienne - Google Patents

Thérapie photodynamique antimicrobienne Download PDF

Info

Publication number
WO2009014524A3
WO2009014524A3 PCT/US2007/016951 US2007016951W WO2009014524A3 WO 2009014524 A3 WO2009014524 A3 WO 2009014524A3 US 2007016951 W US2007016951 W US 2007016951W WO 2009014524 A3 WO2009014524 A3 WO 2009014524A3
Authority
WO
WIPO (PCT)
Prior art keywords
ethylene glycol
glycol units
photosensitizer
vector
microorganism
Prior art date
Application number
PCT/US2007/016951
Other languages
English (en)
Other versions
WO2009014524A2 (fr
Inventor
Nikolay E. Nifantiev
Burkhard Gitter
Dmitri V. Yashunsky
Original Assignee
Ceramoptec Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/880,974 external-priority patent/US20090030257A1/en
Application filed by Ceramoptec Industries, Inc. filed Critical Ceramoptec Industries, Inc.
Priority to BRPI0714667A priority Critical patent/BRPI0714667A8/pt
Priority to MX2009001074A priority patent/MX2009001074A/es
Priority to EP07797049.9A priority patent/EP2049105A4/fr
Priority to US12/375,241 priority patent/US9216166B2/en
Publication of WO2009014524A2 publication Critical patent/WO2009014524A2/fr
Publication of WO2009014524A3 publication Critical patent/WO2009014524A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)

Abstract

La présente invention concerne des conjugués moléculaires antimicrobiens pour le traitement et la prévention de maladies infectieuses provoquées par des micro-organismes pathogens chez des humains et des animaux. L'aspect essentiel de ces conjugués consiste en un espaceur spécial reliant au moins un photosensibilisateur à un récepteur (vecteur) de micro-organismes qui à son tour est lié de manière sélective à la surface d'un micro-organisme entraînant la destruction optique lors d'une irradiation. Des espaceurs ayant une structure hydrophile telle que des motifs d'éthylène glycol et des motifs d'éthylène d'extrémité coiffée d'amine carboxyle doivent être utilisés pour lier le vecteur au photosensiblisateur. Selon un mode de réalisation préféré, un espaceur comprendrait au moins 3 motifs d'éthylène glycol et aurait une extrémité coiffée d'un groupe carboxyle sur une extrémité et d'un groupe amine à l'autre extrémité. La présente invention fonctionne efficacement pour combattre une infection bactérienne dans des environnements réels associés à des patients où du sang, du sérum et d'autres liquides organiques sont constamment présents et au moins à proximité. Dans des modes de réalisation préférés, des espaceurs de longueur et de structure choisies sont utilisés pour lier le vecteur au photosensiblisateur. On a constaté que ces conjugués sont très efficaces pour combattre une infection bactérienne dans des environnements réels associés à des patients où du sang, du sérum et d'autres liquides organiques sont constamment présents et au moins à proximité. L'invention concerne également un procédé d'utilisation.
PCT/US2007/016951 2006-07-27 2007-07-27 Thérapie photodynamique antimicrobienne WO2009014524A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BRPI0714667A BRPI0714667A8 (pt) 2006-07-27 2007-07-27 Conjugado molecular e respectivo uso
MX2009001074A MX2009001074A (es) 2006-07-27 2007-07-27 Terapia fotodinamica antimicrobiana.
EP07797049.9A EP2049105A4 (fr) 2006-07-27 2007-07-27 Thérapie photodynamique antimicrobienne
US12/375,241 US9216166B2 (en) 2006-07-27 2007-07-27 Anti-microbial photodynamic therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83383606P 2006-07-27 2006-07-27
US60/833,836 2006-07-27
US11/880,974 US20090030257A1 (en) 2007-07-25 2007-07-25 Anti-microbial photodynamic therapy
US11/880,974 2007-07-25

Publications (2)

Publication Number Publication Date
WO2009014524A2 WO2009014524A2 (fr) 2009-01-29
WO2009014524A3 true WO2009014524A3 (fr) 2020-10-15

Family

ID=40282008

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016951 WO2009014524A2 (fr) 2006-07-27 2007-07-27 Thérapie photodynamique antimicrobienne

Country Status (4)

Country Link
EP (1) EP2049105A4 (fr)
BR (1) BRPI0714667A8 (fr)
MX (1) MX2009001074A (fr)
WO (1) WO2009014524A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021023915A1 (fr) * 2019-08-02 2021-02-11 Koite Health Oy Procédé d'amélioration de l'action antimicrobienne d'antibiotiques administrés par voie systémique
CN114053406B (zh) * 2021-11-23 2022-12-09 华中科技大学 一种多功能光热纳米杀菌材料及制备与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183245A1 (en) * 1997-03-06 2002-12-05 Tayyaba Hasan Photosensitizer conjugates for pathogen targeting
US20020197261A1 (en) * 2001-04-26 2002-12-26 Chun Li Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
US20030176326A1 (en) * 2002-03-15 2003-09-18 Ceramoptec Industries Inc. Photosensitzers for photodynamic therapy of microbial infections
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20050153371A1 (en) * 2004-01-07 2005-07-14 Ambit Biosciences Corporation Conjugated small molecules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186087A1 (en) * 2003-03-20 2004-09-23 Ceramoptec Industries, Inc. Siderophore conjugates of photoactive dyes for photodynamic therapy
US8153111B2 (en) * 2004-06-18 2012-04-10 Ceramoptec Industries, Inc. Photo-triggered release of active substances from dendrimer-photosensitizer complexes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183245A1 (en) * 1997-03-06 2002-12-05 Tayyaba Hasan Photosensitizer conjugates for pathogen targeting
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20020197261A1 (en) * 2001-04-26 2002-12-26 Chun Li Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
US20030176326A1 (en) * 2002-03-15 2003-09-18 Ceramoptec Industries Inc. Photosensitzers for photodynamic therapy of microbial infections
US20050153371A1 (en) * 2004-01-07 2005-07-14 Ambit Biosciences Corporation Conjugated small molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAVI ET AL.: "The Depth of Porphyrin in a Membrane and the Membrane?s Physical Properties Affect the Photosensitizing Efficiency", BIOPHYSICAL JOURNAL, vol. 82, April 2002 (2002-04-01), pages 2101 - 2110, XP000537839 *

Also Published As

Publication number Publication date
EP2049105A4 (fr) 2022-03-30
MX2009001074A (es) 2009-06-05
WO2009014524A2 (fr) 2009-01-29
BRPI0714667A8 (pt) 2016-10-18
EP2049105A2 (fr) 2009-04-22
BRPI0714667A2 (pt) 2013-08-06

Similar Documents

Publication Publication Date Title
Costley et al. Sonodynamic inactivation of Gram-positive and Gram-negative bacteria using a Rose Bengal–antimicrobial peptide conjugate
Xiao et al. Photosensitizer conjugate-functionalized poly (hexamethylene guanidine) for potentiated broad-spectrum bacterial inhibition and enhanced biocompatibility
MX2013000876A (es) Dihidroxi-clorinas glico-sustituidas y clorinas beta-funcionalizadas para terapia fotodinamica anti-microbiana.
WO2009110940A3 (fr) Phyllosilicates laminés interagissant avec des virus, des bactéries, et des champignons, et procédés d’utilisation
EP2452935A3 (fr) Dérivés de tétracycline pour le traitement d'infections bactériennes, virales et parasites
WO2006079120A3 (fr) Constructions fixant la phosphatidylserine et leur utilisation pour le traitement de maladies
WO2006093891A3 (fr) Photosensibilisateurs pour therapie photodynamique ciblee
BRPI0515520A (pt) composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
EP2357190A3 (fr) Peptides antimicrobiens cycliques
ES2421731T3 (es) Composición y procedimiento para el tratamiento de MRSA
IL187125A0 (en) Phthalocyanine derivatives, process for their preparation, pharmaceutical compositions containing them, and their use
WO2010019717A3 (fr) Thérapie de combinaison d'inhibiteurs de fusion/entrée du vih ciblant gp41
WO2009014524A3 (fr) Thérapie photodynamique antimicrobienne
WO2006109192A8 (fr) Molecules bifonctionnelles antifongiques, procedes de construction et procedes de traitement d'infection fongique avec de telles molecules
WO2004050678A3 (fr) Composes resistant a la desactivation metabolique et procedes d'utilisation
WO2008147468A3 (fr) Phyllosilicates feuilletés interagissant avec un virus, et procédés d'utilisation
JP2006519217A5 (fr)
WO2006003518A3 (fr) Molecules de conjugues de carbohydrate-phosphorylcholine et leur utilisation dans des applications vaccinales, therapeutiques et diagnostiques
WO2003077873A3 (fr) Photoamorceurs pour therapie photodynamique relative aux infections microbiennes
RU2008113403A (ru) Препарат для переработки органических отходов "экос"
Ryu et al. Chlorin e6-mediated photodynamic inactivation with halogen light against microbes and fungus
WO2010111171A3 (fr) Traitements améliorés pour détruire ou affaiblir des micro-organismes pathogènes dans le corps d'un mammifère
EP2250887A3 (fr) Utilisation de l'analogue de tétracycline anti-bactérien CMT-1002, et des formulations de celui-ci, pour le traitement des exotoxines bactériens
WO2008008513A3 (fr) Traitements de combinaison

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 12375241

Country of ref document: US

Ref document number: MX/A/2009/001074

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007797049

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1068/CHENP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07797049

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0714667

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090123